Roche in $1 billion RNAi deal with Alnylam Pharmaceuticals

Share this article:

Swiss drugmaker Roche said it has entered a deal worth up to $1 billion with Alnylam Pharmaceuticals to gain access to the Cambridge, MA-based firm's skills in RNA interference (RNAi) technology.

Under the deal, Roche will pay Alnylam $331 million upfront in cash and equity investment. Future payments will be made upon reaching certain milestones.

The deal also makes Roche a co-investor in Alnylam, along with Swiss rival Novartis, which purchased a 19.9% stake in Alnylam in 2005.

Last month, Alnylam said it had begun a Phase II clinical trial of ALN-RSV01 to treat respiratory syncytial virus that infects the upper and lower respiratory tract, usually in children and people with weak immune systems.

RNAi is considered one of the hottest areas in biotechnology research and was the basis for last year's Nobel Prize in medicine. It is seen as having potential to produce promising treatments for cancer, blindness and AIDS.

Last October, Merck paid $1.1 billion for RNAi technology-based treatment development firm Sirna Therapeutics. Since then, other drugmakers including Pfizer, have struck a series of RNAi product development deals.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...